Clinical trials are ongoing using small molecule-targeting protein kinase D, which is involved in pancreatic cancer [190], and insulin-like growth factor-1 receptor (IGF-1R) that is involved in MAPK and PI3K/Akt pathways and also cross-talks with EGFR pathway. Here, IGF1R is linked to pancreatic neoplasm.